Huang Lin
Chief Pharmacist, Associate Professor, Master’s Supervisor (Academic & Professional), School of Pharmaceutical Sciences
Research Interests: Individualized Drug Therapy, Mechanisms of Adverse Drug Reactions
Tel: +86-010-88325750
Email: huanglin@pkuph.edu.cn
EDUCATION
Doctor of Medicine, Tongji Medical College, Huazhong University of Science and Technology (2008)
Bachelor of Medicine, Tongji Medical College, Huazhong University of Science and Technology (2004)
PROFESSIONAL EXPERIENCE
2024.11 – present Department of Pharmacy, Peking University People’s Hospital, Deputy Director
2022.08 – present Department of Pharmacy, Peking University People’s Hospital, Secretary of the Communist Party of China Branch
2020.08 – present Department of Pharmacy, Peking University People’s Hospital, Associate Professor
2018.12 – present Department of Pharmacy, Peking University People’s Hospital, Academic Assistant / Clinical Pharmacy Group Leader
2017.10 – 2018.09 School of Pharmacy, University of Pittsburgh, Senior Visiting Scholar
2017.08 – present Department of Pharmacy, Peking University People’s Hospital, Chief Pharmacist
2012.08 – 2017.07 Department of Pharmacy, Peking University People’s Hospital, Associate Chief Pharmacist
2008.08 – 2012.07 Department of Pharmacy, Peking University People’s Hospital, Supervisor Pharmacist
ACADEMIC APPOINTMENTS
Standing Committee Member, Pharmacoeconomics Professional Committee, Chinese Research Hospital Association
Committee Member, Drug-Induced Diseases Professional Committee, Chinese Pharmacological Society
Committee Member, Medication Therapy Management Working Committee, Chinese Pharmacists Association
Committee Member, Geriatric Pharmacy Professional Committee, China Medical Education Association
Standing Committee Member, Quantitative Pharmacology Professional Committee, Beijing Pharmacological Society
Committee Member, Clinical Pharmacy Branch, Beijing Medical Association
Committee Member, Clinical Research and Translation Professional Committee, Beijing Pharmaceutical Association
Editorial Board Member, China Pharmacy Journal
Corresponding Editorial Board Member, Adverse Drug Reactions Journal
AWARDS AND CERTIFICATES
Outstanding Clinical Pharmacist, Clinical Pharmacy Branch of Chinese Medical Association (2016-2017)
Clinical Pharmacy Star, Beijing Pharmaceutical Association (2013-2014)
Outstanding Communist Party Member, Peking University People’s Hospital (2013-2014, 2016-2017, 2019-2020, 2020-2021)
REPRESENTATIVE PUBLICATIONS
1. Yuanyuan Li*, Nan Guo*, Yinyu Zhao, Jiali Chen, Jinxia Zhao, Jialu Bian, Jing Guo, Changqing Yang, Xiaohong Zhang, Lin Huang#. IL-17A Activates JAK/STAT Signaling to Affect Drug Metabolizing Enzymes and Transporters in HepaRG Cells [J]. Molecular Immunology, 2024 Nov:175:55-62.
2. Yinyu Zhao, Nan Guo, Yidan Zhu, Jingyuan Shang, Jiali Chen, Xingxian Luo, Yi Liu, Xiaohong Zhang#, Lin Huang#. Population pharmacokinetic models of venetoclax in hematologic malignancies: A systematic review [J]. Drug Design Development and Therapy, 2024 May 27: 18: 1771-1784.
3. Yuanyuan Li#, Ying Zhang#, Jinxia Zhao, Jialu Bian, Yinyu Zhao, Xu Hao, Boyu Liu, Lei Hu, Fang Liu, Changqing Yang, Yufei Feng#, Lin Huang#. Combined Impact of Hypoalbuminemia and Pharmacogenomic Variants on Voriconazole Trough Concentration：data from a real-life clinical setting in the Chinese population [J]. Journal of Chemotherapy, 2024 May;36(3):179-189.
4. Xu Hao*, Yuanyuan Li*, Ying Zhang, Jialu Bian, Jinxia Zhao, Yinyu Zhao, Lei Hu, Xingxian Luo, Changqing Yang, Yufei Feng, Lin Huang#. Individualized treatment with voriconazole in the Chinese population: inflammation level as a novel marker for dose optimization [J]. British Journal of Clinical Pharmacology, 2024 Feb; 90(2): 440-451.
5. Xingxian Luo*, Lin Huang*, Xin Du*, Yue Yang, Xufeng Lv, Xiaohong Zhang#. Current regulatory status in China of drugs withdrawn from the US FDA accelerated pathway: implications for regulation globally. [J]. Lancet Oncology. 2024;25(6):703-706.
6. Xingxian Luo*, Xin Du*, Xufeng Lv, Yue Yang, Xiaohong Zhang#, Lin Huang#. Clinical Benefit, Price, and Regulatory Approval of Cancer Drugs Granted Breakthrough Therapy Designation in China, 2020-2024. JAMA Netw Open. 2024 Oct 1;7(10):e2439080.
7. Xingxian Luo, Yang Xu, Xin Du, Xufeng Lv, Si Chen, Yue Yang#, Lin Huang#, Xiaohong Zhang#. Progress and challenges of confirmatory trials for cancer drugs granted conditional approval in China. Lancet Reg Health West Pac. 2024 Nov 7;52:101238.
8. Chaoqun Ma, Xiaolei Ren, Pang Ning, Liu Yingkun, Chen Meifang, Zhang Xiaohong, Liu Yi#, Lin Huang#. Incidence, characteristics, and risk factors of hypofibrinogenemia induced by generic tigecycline: a retrospective study. Naunyn Schmiedebergs Arch Pharmacol. 2024 Sep 10.
9. Chunyan Zhang, Xiaolei Ren, Jing Huang, Lin Huang#, Xiaohong Zhang#. Central serous chorioretinopathy secondary to systemic corticosteroids: a case report and review of the literature. [J]. Expert Opin Drug Saf. 2024, Aug 2: 1-5.
10. Xia Si, Hongyan Zhang, Qingming Ding, Gang Liu, Lin Huang#, Xin Sun#. Retrospective analysis of real-world prescribing data for managing cisplatin-based chemotherapy-induced nausea and vomiting in China [J]. Cancer Med 2024 Mar;13(6): e7121.
11. Chunyan Zhang*, Xiaolei Ren*, Liu Yi, Lin Huang#, Yufei Feng, Zhang Xiaohong#. Effects of Wuzhi Capsule on Whole-Blood Tacrolimus Concentration Levels: A Systematic Review and Meta-Analysis. Ther Drug Monit. 2024 Feb 1;46(1):33-41.